In Africa, pregnant women and young children are the most vulnerable to malaria.
However, malaria control interventions and strategies have achivied important results in the last years.
COVID-19 has now made these interventions critical, and could undo the results obtained so far, as highlighted by scientists in the Lancet: https://bit.ly/2Tfyxwn.
Potentially, COVID-19 could indirectly cause more deaths than it already does directly, in the context of Africa’s weak and fragile health systems.
The spread of Mpox virus (MPXV) in Sub-Saharan Africa, specifically Democratic Republic of Congo (DRC) and Republic of Congo (RoC) presents an urgent public health concern with global implications. MPXV cases
Ebola vaccine candidates are currently being evaluated in phase I–III clinical trials conducted in Africa, the EU and the US. Although preclinical development of candidate vaccines utilise different platforms, including
As part of the implementation of ITAIL-COVID-19 project funded by the European Development Countries Partnership for Clinical Trials (EDCTP) and coordinated by the Congolese Foundation for Medical Research (FCRM), the